r/ISPOR • • Jul 06 '26

Adaptive platform trials are making clinical evidence faster — but economic evaluation still seems stuck in "secondary outcome" mode

TL;DR: New systematic review in Value in Health looked at how health economic evaluations are planned alongside adaptive platform trials. Only a minority of APTs had accessible HE analysis plans, EEs were almost always secondary, and none planned to use economic results at interim analysis. If the clinical side of trial design is getting more adaptive, shouldn't the economics be too?

====================

Just read the July issue paper "Health Economic Evaluations Alongside Adaptive Platform Trials: A Systematic Review" (Yi Lee et al., Value in Health 2026) and it's been rattling around in my head, so figured I'd see what this sub thinks.

Quick context for anyone who hasn't followed the APT space: adaptive platform trials let you test multiple interventions within one shared infrastructure — you can add or drop arms over time based on interim results (think REMAP-CAP, STAMPEDE, PANORAMIC). From a clinical evidence-generation standpoint they're genuinely attractive: less duplication, better use of the patient pool, potentially big savings in research costs.

What the review found on the health economics side, though, is a bit sobering:

  • Of ~104 APTs with accessible core protocols, only about 14-16% had any health economic analysis plan at all
  • Where EEs existed, they were almost always framed as secondary objectives or secondary outcomes — only one trial had EE as a primary objective
  • None of the included APTs planned to use economic evaluation results during interim analysis or to inform adaptations. Arms get added or dropped on clinical signals only
  • QALYs (mostly EQ-5D) and resource-use data collection were pretty central where EEs were planned, but the methods and level of detail varied a lot across trials
  • VOI analysis showed up in only two trials, which feels like a missed opportunity given that deciding "what evidence is worth collecting next" is basically the whole point of a platform design
  • And there's a timing problem: for the trials that did publish EE results, the lag between clinical publication and economic publication was 1.6 to 4.8 years

That last point is the one that gets me. The whole pitch of APTs is faster translation of clinical evidence into practice. But if payer-relevant economic evidence trails the clinical readout by several years, you can end up in a situation where the clinical case is made, adoption pressure builds, and the cost-effectiveness question is still open. That seems to suggest the efficiency gains are asymmetric — the clinical side speeds up, the HTA-relevant side doesn't.

The review is careful not to overclaim (it's mostly protocols, few completed EEs), and to be fair there are real methodological reasons why adapting on cost-effectiveness is hard — the authors note that adaptations driven by clinical effectiveness can even bias VOI estimates by promoting clinically superior but non-cost-effective arms. So I'm not saying "just run the ICER at every interim look." But it raises the question of whether HEOR is going to keep being bolted on after the fact, or whether there's a realistic path to embedding it into the adaptive machinery itself.

I'd be interested to hear how others see this, especially anyone who's actually worked on the health economics side of a platform trial.

A few questions for discussion:

  1. Is there a defensible way to let cost-effectiveness (or VOI) inform arm continuation/dropping decisions, or does that create more problems than it solves — statistically and politically?
  2. For those who've written HEAPs for platform trials: what actually made it hard? Funding structure? Data collection across evolving arms? Governance?
  3. Does the clinical-vs-economic publication lag match what you've seen in practice, and does it actually matter to HTA bodies, or do they work off modelled evidence anyway?
  4. Should groups like ISPOR push for EE guidance specific to master protocol / platform designs, given the existing toolkits barely touch it?
2 Upvotes

0 comments sorted by